ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CLLS Cellectis SA

2.65
-0.02 (-0.75%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 44,068
Bid Price 2.65
Ask Price 2.75
News -
Day High 2.75

Low
0.962777

52 Week Range

High
3.7735

Day Low 2.65
Company Name Stock Ticker Symbol Market Type
Cellectis SA CLLS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.75% 2.65 17:14:56
Open Price Low Price High Price Close Price Prev Close
2.71 2.65 2.75 2.65 2.67
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
212 44,068 $ 2.68 $ 117,935 - 0.962777 - 3.7735
Last Trade Time Type Quantity Stock Price Currency
17:14:37 1 $ 2.65 USD

Cellectis SA Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
118.3M 45.68M - 27.67M -106.14M -2.32 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cellectis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CLLS Message Board. Create One! See More Posts on CLLS Message Board See More Message Board Posts

Historical CLLS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.412.752.362.5621,4010.249.96%
1 Month2.572.782.35012.5429,6320.083.11%
3 Months2.903.132.35012.7741,673-0.25-8.62%
6 Months1.593.77350.9627772.73988,5221.0666.67%
1 Year2.043.77350.9627772.69523,4680.6129.90%
3 Years19.0521.460.9627775.08295,902-16.40-86.09%
5 Years17.7234.710.9627779.69255,752-15.07-85.05%

Cellectis Description

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Your Recent History

Delayed Upgrade Clock